Table 3.
Study |
Rate of received |
Adverse effect on OS | Adverse effect on CSS | Adverse effect on RFS | Adverse effect on PCs |
BTF patients | |||||
Sun et al[1], 2015 | 36.3% | Yes, | Yes, | Yes, | Not specified |
HR, 2.17; | HR, 2.57; | HR, 1.52; | |||
95%CI, 1.86-2.37 | 95%CI, 1.24-5.34 | 95%CI, 1.08-2.15 | |||
Li et al[2], 2015 | 44.8% | Yes, | Not specified | Yes, | Yes, |
HR, 1.26; | |||||
HR, 1.36; | HR, 3.33; | ||||
95 % CI, 1.21-1.31 | |||||
95%CI, 1.02-1.81 | 95%CI, 1.02-1.81 | ||||
Agnes et al[3], 2018 | Not specified | Yes, | Yes, | Yes, | Yes, |
HR, 1.34; | HR, 1.66; | HR, 1.48; | HR, 1.36; | ||
95%CI, 1.23-1.45 | 95%CI, 1.50-2.19 | 95%CI, 1.18-1.86 | 95%CI, 2.10-5.29 |
BTF: Blood transfusion; OS: Overall survival; CSS: Cancer-specific survival; RFS: Relapse-free survival; PCs: Postoperative complications; HR: Hazard ratio; CI: Confidence interval.